[ Price : $8.95]
FDA accepts for review a Cingulate NDA for CTx-1301 (dexmethylphenidate), a once-daily stimulant designed to treat attention-defic...[ Price : $8.95]
An Astellas Phase 2 study evaluating zolbetuximab in combination with standard chemotherapy for metastatic pancreatic cancer fails...[ Price : $8.95]
FDA publishes a guidance with recommendations for submitting clinical trial data sets for response assessments for treatments of a...[ Price : $8.95]
Pfizer says its Tukysa met the progression-free survival endpoint in the HER2CLIMB-05 breast cancer trial combining Tukysa with st...[ Price : $8.95]
FDA accepts for review a Rocket Pharmaceuticals BLA resubmission for Kresladi (marnetegragene autotemcel), a gene therapy for seve...[ Price : $8.95]
FDA approves an expanded indication for Teva and Medincells Uzedy (risperidone) to permit its use as monotherapy or adjunctive the...[ Price : $8.95]
Tvardi Therapeutics says its experimental drug TTI-101 failed to show benefit in a Phase 2 clinical trial for idiopathic pulmonary...[ Price : $8.95]
Regeneron says new clinical data show its investigational gene therapy DB-OTO has restored meaningful hearing in nearly all childr...